HC Wainwright Cuts Earnings Estimates for Nurix Therapeutics
Investment analysts at HC Wainwright cut their Q1 2025 earnings estimates for shares of Nurix Therapeutics in a research report issued on Wednesday, January 29th. HC Wainwright analyst R. Burns now ...
Valneva (NASDAQ:VALN) Earns Buy Rating from HC Wainwright
Valneva (NASDAQ:VALN – Get Free Report)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a report released on Friday,Benzinga reports. They currently have a $18.00 price target on the stock ...
The Armenian Reporter20h
HC Wainwright Begins Coverage on Knightscope (NASDAQ:KSCP)
Equities researchers at HC Wainwright started coverage on shares of Knightscope (NASDAQ:KSCP – Get Free Report) in a research note issued on Thursday, MarketBeat Ratings reports. The brokerage set a ...
The Armenian Reporter18h
HC Wainwright Issues Positive Forecast for Vertex Pharmaceuticals (NASDAQ:VRTX) Stock Price
Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its price objective raised by HC Wainwright from $535.00 to $550.00 in a research note released on Friday,Benzinga reports. HC Wainwright ...
Vertex Pharmaceuticals price target raised to $433 from $430 at Scotiabank
Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $433 from $430 and keeps a Sector Perform rating on the shares. Vertex’s suzetrigine, branded Journavx, was recently ...